Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 12s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

A Research To Evaluate The Relationship Regarding Steatotic Liver Damage Or Metabolic Dysfunction: A Comprehensive Analysis Of A Complex Issue

Dai Decai[1], Satheesh Babu Natarajan[2]

Cite this paper as: Dai Decai, Satheesh Babu Natarajan, (2025) A Research To Evaluate The Relationship Regarding Steatotic Liver Damage Or Metabolic Dysfunction: A Comprehensive Analysis Of A Complex Issue. *Journal of Neonatal Surgery*, 14 (12s), 375-380.

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) is becoming increasingly common; it affects over 25% of the global population and over 60% of those at high risk. It raises the probability of metabolic syndrome, which includes several diseases affecting the liver and cardiovascular system. The intricacy of NAFLD, as well as the comorbidities and complications that often accompany it, make a multidisciplinary approach to treatment essential. Experts are concerned about the lack of understanding regards to NAFLD, including its seriousness, potential consequences, comorbidities, and what to do if NAFLD is found. Those who have cirrhosis, inflexible simple steatosis, hepatocellular cancer, or cardiovascular disease and are actively metabolizing non-alcoholic steatosis (NASH) need to be located. This could be difficult since there are competing opinions on the best ways to diagnose and treat the problem. Before discussing possible future prospects for multidisciplinary care route development, the researchers review the history of NAFLD, its diagnostics, and treatment choices.

Keywords: *Steatotic liver disease, dysfunction of metabolism, diagnosis.*

1. INTRODUCTION

An unhealthy fixation on food and insufficient physical activity, sometimes referred to as the "Western lifestyle," has seen a meteoric rise in its followers (Battistella et al., 2023). The metabolic syndrome is linked to a "Western lifestyle" and consists of obesity, abnormal lipid profiles, elevated blood sugar, an increase in belly fat, and hypertension. As an aspect of metabolic syndrome, hepatic problems called "nonalcoholic fatty liver disease (NAFLD)" might manifest. A diagnostic criterion for "Non-alcoholic fatty liver disease (NAFLD)" is the presence of intracellular fat in over 5% of hepatocytes, as shown by imaging or histological studies. This condition must be present in the absence of other hepatic steatosis causes, such as excessive alcohol consumption, specific metabolic abnormalities, or medication use (Riazi et al., 2022). Along with obesity and metabolic disorder epidemics, the prevalence of non-alcoholic fatty liver disease (NAFLD) has skyrocketed, affecting over 25% of the global population. More than 60% of high-risk groups are estimated to develop type 2 diabetes mellitus (T2DM). As a whole, "Non-alcoholic fatty liver disease (NAFLD)" and its comorbidities—such as type 2 diabetes and cardiovascular disease—influence healthcare expenditures, quality of life, and death rates. A continuum characterizes the NAFLD phases. Cirrhosis, fibrosis, "Nonalcoholic fatty liver (NAFL)", and "Hepatocellular carcinoma (HCC)" are some of the stages that might appear in a liver disease. There is a small fraction of people with hepatic steatosis who may have severe liver disease, even though "Nonalcoholic fatty liver disease (NAFLD)" is common in the general population. Liver failure, hepatic encephalopathy, esophageal varices, ascites, and HCC are among the consequences that might develop when NAFLD progresses to a more severe type of liver disease. If a patient does not have a history of cardiovascular disease, liver disease, or hepatocellular cancer, it is more important to diagnose metabolically active NASH than non-progressive simple steatosis. various people have various ideas on how to identify these vulnerable people and how to aid them, and it might be difficult to find them. Because of this, many doctors and nurses are confused when they get a new diagnosis of NAFLD or suspect that their patients may have the illness. The lack of a unified strategy for treating NAFLD that considers all its manifestations and possible outcomes is a major issue (Henry L, 2022).

Figure 1: The range of symptoms associated with NAFLD is wide.



Aiming to cover every angle of non-alcoholic fatty liver disease (NAFLD), the participants will provide a rundown of diagnostic tests, clinical therapy choices, and treatment plan recommendations.

2. BACKGROUND OF THE STUDY

A major public health concern, non-alcoholic fatty liver disease (NAFLD) is associated with cardiometabolic comorbidities (Horn & Newsome, 2022). Primary care physicians, vascular specialists, hepatologists, internists-endocrinologists, and nursing assistants all need to work together as a multidisciplinary team to identify patients at high risk of developing NASH. A few hospitals throughout the world have started NASH workgroups to encourage cooperation in this field. Patients diagnosed with non-alcoholic fatty liver disease (NAFLD) may not necessarily have metabolically active NASH, cirrhosis, non-progressive simple steatosis, or hepatocellular carcinoma (HCC). Major health problems, such as cardiovascular disease, are more common in these groups. Improved screening and stage distinction in liver disease, as well as the determination of the severity and likelihood of cirrhotic consequences like HCC, need more precise and non-invasive diagnostic methods. The non-invasive diagnostic instrument that is both accurate and generally accessible is currently unavailable; thus, the methods shown in Fig. 2 provide ways to screen for, diagnose, and monitor individuals who may have NAFLD. People at high risk for nonalcoholic fatty liver disease (NAFLD) should undergo screening with ultrasonography or serum liver enzyme testing every three years. Every six months, patients with severe fibrosis or cirrhosis should have their HCC checked. (Chew et al., 2022) recommends that in addition to treating portal hypertension, esophageal varices be considered.

Figure 2: Approaching non-alcoholic fats liver disease (NAFLD) from several perspectives.



3. PURPOSE OF THE RESEARCH

The main goal of this study was to look at how faecal microbiota transplantation (FMT) affected people with metabolic syndrome and non-alcoholic fatty liver disease (NAFLD). Comparing the results of autologous (from self) and allogeneic (from donors) FMT in treatment-naïve NAFLD patients was the primary goal of the research. Find out how FMT affects the makeup of the gut microbiota, plasma metabolomics, and patterns of DNA methylation in the liver, all of which play a part in NAFLD. In a 24-week period, use these biological indicators to train a machine learning model that can differentiate between patients receiving autologous and heterologous FMT. add to the growing body of knowledge on the gut-liver axis in NAFLD and the therapeutic possibilities it has for researchers. Look into the potential of using multi-omics data to predict and tailor the effectiveness of FMT therapy for NAFLD patients. Describe the process by which FMT works to treat NAFLD and provide the framework for further research into its effectiveness. The study aimed to enhance our knowledge of non-alcoholic fatty liver disease (NAFLD) and its possible causes and therapies by investigating these aims, with a focus on the gut microbiota. Plus, it allowed for more tailored and efficient remedies for a disease that is becoming more common (Chauhan et al., 2022).

4. LITERATURE REVIEW:

Alcoholic hepatitis may progress into cirrhosis of the liver even in moderate drinkers. Most people with diabetes mellitus were somewhat obese, according to Boursier et al. (2022). This condition affecting the liver is known medically as chronic non-alcoholic steatohepatitis. Ultrasonography results can be used to diagnose non-alcoholic fatty liver disease (NAFLD) after other potential causes, such as chronic liver disease, excessive alcohol consumption, or medications that cause hepatic stenosis, have been ruled out, according to the guidelines established by the Asian-Pacific Sitting Party for NAFLD. Despite NAFLD being diagnosed by ruling out other causes of chronic liver disease, the European Association for the Study of Liver (EASL) later released a position statement acknowledging that the term should be rebranded because of its strong correlation with metabolic syndrome and overlap with other chronic liver disorders. The acronym NAFLD was still in use for major international recommendations 4-6, but that would soon change. While using the term "primary NAFLD," the 2016 guidelines characterized NAFLD as being "associated with metabolic risk factors." " Consider this carefully. In its 2017 recommendations, the Asian-Pacific Research Party (Hamurcu Varol et al., 2020) offered a "positive" definition of NAFLD.Fatal liver disease connected with metabolic processes malfunction is a new word I came up with not long ago. Individuals who have a family history of type 2 diabetes (T2DM), are overweight, have imaging evidence of liver steatosis, or have biomarkers in their bloodstream may be diagnosed with this illness. The Asian Pacific Association for the Statistical Investigation of the Liver and the Malaysian Society of Gastro and Hepatology are only two of the several international organizations that have endorsed this. A multi-society Delphi compromise statement on the alternative nomenclature for fatty liver disease was released in June 2022, thus abandoning the name NAFLD in favor of mitochondrial dysfunction-associated steatosis hepatitis sickness. Better possibilities include MAFLD and MASLD since they describe the same subject more thoroughly. As stated by (Ng et al., 2022).

Table 1

Characteristic	MAFLD
Positive diagnostic criteria	Yes
Attributes the condition to its etiology	Yes
Criteria	Hepatic steatosis detected either by imaging techniqu
Presence of other concomitant liver diseases	Other concomitant liver diseases retain their own terr

*MetALD, i.e., weekly intake 140–350 g for female, 210–420 g for male (average daily 20–50 g for female, 30–60 g for male).

Abbreviations:
MAFLD: metabolic dysfunction-associated fatty liver disease
MASLD: metabolic dysfunction-associated steatotic liver disease
HDL: high-density lipoprotein
HbA1c: glycosylated hemoglobin
HOMA-IR: homeostatic model for assessment of insulin resistance
hs-CRP: high sensitivity C-reactive protein
BMI: body mass index
MetALD: MASLD and increased alcohol intake

5. RESEARCH QUESTIONS

- What is the impact of high cholesterol on steatotic liver disease?

6. RESEARCH METHODOLOGY

This study is a part of the LITMUS project, a global multi-center effort to find and validate a collection of biomarkers for NASH and NAFLD-related fibrosis diagnosis. It is possible for the ordinary person to see the whole systematic review procedure. We followed the guidelines laid forth by the PRISMA-DTA statement while writing this report. Researchers used an innovative search technique to scour the literature for articles that assessed the diagnostic accuracy of Pro-C3 in NAFLD patients. Using Medical Subject Headings, the search approach included the whole record, including its abstract and title. In 2022, a plethora of databases were queried, such as MEDLINE (via OVID), EMBASE (through OVID as well), PubMed, Academic Citations Index, and CENTRAL (the Collaborative Library). Researchers may have a whole search strategy at their fingertips with the supplement. They reached out to other LITMUS members and went through the bibliographies of qualified research articles by hand to find other studies that the search method could have missed. Changes were made to the search in 2022. Up to that point, it had checked every record that matched the criteria set by the researchers.

7. CONCEPTUAL FRAMEWORK



8. RESULTS

Histologic (n = 10) and immunological (n = 11) fecal microbiota transplantation (FMT) were used to treat metabolic syndrome and hepatic steatosis in 21 individuals who had never received any therapy before. The study did not include those who had cholecystectomy, diabetes (especially type 2), heart disease, kidney disease, or impaired immune function in the past. No one in the group idles out medication. You may find a detailed list of inclusion/exclusion criteria elsewhere. Table 2 shows where the study participants started. Importantly, neither the food intake nor the age of the treatment groups differed significantly at baseline (Suppl. Table 2). Baseline steatosis percentage, fibrosis stage, and NAFLD action score (NAS) did not vary significantly across the groups. Basic information on 21 individuals with NAFLD confirmed by biopsy is shown in Table 2. Common ways to display data include the median (interquartile range), the percentage frequency, or the mean plus or minus the standard deviation. The p-values reflect the results of many statistical tests, including Fisher's exact test for binary data, the t-test for regularly distributed information, and the Mann-Whitney U test for independent data. The abbreviations "ALP," "ALT," and "AST" are used for glutamate transaminase, aspartate, and "BMI," specifically for the proteins. When we talk about cholesterol, the abbreviations for high-density lipoprotein (HDL) and low-density lipoprotein (LDL) are HDL-C and LDL-C, respectively. Feeding the gut microbiota, C-reactive protein, and alpha-glutamyl transferase. The NAFLD Activity Score is what the NAS score stands for. The acronym for type 2 diabetes mellitus.

Table 2

Characteristic	Autologous FMT (n=11)	Allogenic FMT (n=10)	p-value
Age, years	48.5 ± 10.2	51.2 ± 6.6	0.48
Sex, male/female	10/1	7/3	0.31
BMI, kg/m²	31.5 ± 4.8	31.7 ± 3.5	0.91
HbA1c, mmol/mol	37.6 ± 3.8	38.2 ± 3.7	0.70
Glucose, mmol/L	5.7 ± 0.5	5.8 ± 0.7	0.79
AST, IU/L	29.0 [26.5–33.0]	39.5 [37.0–49.5]	0.001
ALT, IU/L	48.1 ± 16.5	70.8 ± 23.4	0.02
ALP, IU/L	83.0 [54.0–120.5]	71.0 [58.8–76.8]	0.67
GGT, IU/L	41.1 ± 21.4	45.1 ± 19.3	0.66
Cholesterol, mmol/L	5.8 ± 1.6	6.0 ± 0.8	0.75
HDL-C, mmol/L	1.2 [1.0–1.4]	1.2 [1.0–1.4]	0.80
LDL-C, mmol/L	4.0 ± 1.3	4.2 ± 0.7	0.71
Triglycerides, mmol/L	1.2 ± 0.6	1.4 ± 0.5	0.41
CRP, mg/mL	2.2 [0.8–4.3]	1.5 [0.9–3.2]	0.50
Steatosis, %	35.0 ± 20.7	34.1 ± 20.4	0.92
NAS score			0.38
1	1 (9%)	0 (0.0%)	
2	5 (46%)	4 (40%)	
3	4 (36%)	2 (20%)	
4	1 (9%)	4 (40%)	
Necro-inflammation score			0.06
0	1 (9%)	0 (0%)	
1	10 (91%)	6 (60%)	
2	0 (0%)	4 (40%)	
Fibrosis stage			1.00
F0	3 (30%)	2 (20%)	
F1	6 (60%)	5 (50%)	
F2	2 (20%)	2 (20%)	
F3	0 (0%)	1 (10%)	

Intestinal microbiota alterations (AUC0.78), plasma metabolisms (AUC0.74), and DNA methylation patterns in the liver (AUC0.75) were the endpoints that the predictive machine learning algorithm used to distinguish between allogenic and allogeneic FMT from 0 to 24 weeks. The results of the permutation research demonstrated that there was a very low probability (0.88; $p < 0.001$) that the acquired accuracy was due to chance alone. Below, we outline the main features that differentiate each group in each study.

9. CONCLUSION

The accordance with these findings, a novel approach to drug response prediction has been developed by merging omics data with machine learning (Lubner et al., 2021). The findings of this research also add credence to the idea that FMT might be useful in the medical management of non-alcoholic fatty liver disease. This work adds to what is already known about the gut-liver link in NAFLD and opens new possibilities for creating tailored treatments for this common condition (Tamaki et al., 2022).

REFERENCES

[1] Tamaki N, Munaganuru N, Jung J, Yonan AQ, Loomba RR, Bettencourt R, Ajmera V, Valasek MA, Behling C, Sirlin CB, Loomba R. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut. 2022; 71:983–990.

[2] Lubner MG, Graffy PM, Said A, Watson R, Zea R, Malecki KM, Pickhardt PJ. Utility of Multiparametric CT for Identification of High-Risk NAFLD. AJR Am J Roentgenol. 2021; 216:659–668.

[3] Boursier J, Hagström H, Ekstedt M, Moreau C, Bonacci M, Cure S, Ampuero J, Nasr P, Tallab L, Canivet CM, Kechagias S, Sánchez Y, Dincuff E, Lucena A, Roux M, Riou J, Trylesinski A, Romero-Gomez M. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. J Hepatol. 2022; 76:1013–1020.

[4] Hamurcu Varol P, Kaya E, Alphan E, Yilmaz Y. Role of intensive dietary and lifestyle interventions in the

treatment of lean nonalcoholic fatty liver disease patients. Eur J Gastroenterol Hepatol. 2020; 32:1352–1357.

[5] Ng CH, Lin SY, Chin YH, Lee MH, Syn N, Goh XL, Koh JH, Quek J, Hao Tan DJ, Mok SF, Tan E, Dan YY, Chew N, Khoo CM, Siddiqui MS, Muthiah M. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence from a Network Meta-Analysis of Randomized Controlled Trials. Endocr Pract. 2022; 28:223–230.

[6] Chauhan M, Singh K, Thuluvath PJ. Bariatric Surgery in NAFLD. Dig Dis Sci. 2022; 67:408–422.

[7] Chew NWS, Ng CH, Truong E, Noureddin M, Kowdley KV. Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. Semin Liver Dis. 2022; 42:379–400.

[8] Horn P, Newsome PN. Nonalcoholic Fatty Liver Disease. N Engl J Med. 2022; 386:294.

[9] Battistella S, D'Arcangelo F, Grasso M, Zanetto A, Gambato M, Germani G, Senzolo M, Russo FP, Burra P. Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management. Clin Mol Hepatol. 2023;29: S286–S301.

[10] Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen AA. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7:851–861.